1637573-04-6

1637573-04-6 structure

Name: Ralaniten triacetate
Chemical Name: Ralaniten triacetate
CAS Number: 1637573-04-6
Molecular Formula: C₂₇H₃₃ClO₈
Molecular Weight: 521.00
Catalog: Signaling Pathways Others Androgen Receptor
Create Date: 2020-08-11 16:01:33
Modify Date: 2025-08-27 19:21:15
Ralaniten triacetate (EPI-506), the pro-drug of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2].

Name	Ralaniten triacetate

Description	Ralaniten triacetate (EPI-506), the pro-drug of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Androgen Receptor
In Vitro	Ralaniten triacetate (EPI-506) targets the N-terminal domain of the androgen receptor (AR), and is used for metastatic castration-resistant prostate cancer (mCRPC) research. EPI-506 is a first-in-class, highly-specific small molecule that binds to a novel target on the AR, the N-terminal domain (NTD) and directly inhibits AR transcriptional activity by blocking the interaction of the AR with transcriptional proteins[2].
References	[1]. Obst JK, et al. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019;2(6):453-467. Published 2019 Sep 26. [2]. Chi, Kim Nguyen et al. Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone. Journal of Clinical Oncology 35 (2017): 5032-5032.

Molecular Formula	C₂₇H₃₃ClO₈
Molecular Weight	521.00